Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 29, 2021, Andrea Acosta, the Group Vice President, Chief Accounting
Officer, and principal accounting officer of BioMarin Pharmaceutical Inc.
("BioMarin" or "the Company") notified BioMarin of her decision to resign,
effective as of January 28, 2022 (the "Effective Date"), in order to pursue
another career opportunity.
The Company will initiate a search for Ms. Acosta's successor. In the event that
the Company has not appointed a successor on or prior to the Effective Date,
Brian Mueller, BioMarin's Executive Vice President, Finance and Chief Financial
Officer, will serve as the Company's principal accounting officer from the
Effective Date until Ms. Acosta's successor is appointed. Mr. Mueller will
continue to serve as BioMarin's Executive Vice President, Finance and Chief
Financial Officer. Mr. Mueller's biographical information is disclosed in the
Company's Proxy Statement for its 2021 annual meeting of stockholders.
Mr. Mueller has not engaged in any transaction that would be reportable as a
related party transaction under Item 404(a) of Regulation S-K. Mr. Mueller will
not receive any adjustment to his compensation or any additional compensation in
connection with performing the functions of the principal accounting officer of
the Company.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses